Start Pharmaceutical Development Company

The process of developing a drug and getting it on the market is extremely expensive. Studies have shown that the cost can range from 161 million to over 2 billion dollars. The Tufts center for drug development found that getting a drug from its initial state to pharmacy shelves cost an astounding 2.5 billion dollars in 2014. This is significantly higher than the 800 million cost associated with bringing new drugs to the market in 2003. These figures are so high in part because they take into account the opportunity cost of investing money in drugs while it could have been invested elsewhere. Another portion of the cost is also due to the failure of drugs. The probability of a pioneer drug advancing past the clinical studies is around 8%. So in order to be profitable, large companies have to invest their time and resources in more than one drug at a time. For every drug they put on the market there are several that took up resources but ultimately did not make it. In addition to the cost, the whole process can take from 10 to 15 years.

1. Pricing: Many Asian and African countries are poor and cannot afford the costly medicines. The Pharmaceutical firms spend vast amounts on R&D in creating and marketing drugs, thus charging high prices enables for cost of capital recovery and profit generation.

Prescription drug prices are on the rise in the United States. Currently, the United States does not implement a price control on prescription drugs. Every day the supply and demand for prescription drugs fluctuates. Pharmaceutical companies produce drugs that are necessary for survival. Therefore, it is necessary for research and development to continue in the United States. Those suffering the effects of exorbitant prices must do so until a generic form of a prescription drug is produced. Once approved by the FDA, new drugs will make their appearance on the market and patients will no longer suffer financially. Until then, it is necessary for pharmaceutical companies to price their drugs based on the idea of supply and demand. This produces the profit used to fund research. Price controls discourage innovation. If a price control were set in place, of course the price of prescription drugs would decrease. However, the development of new drugs decreases with it. Today’s generation would benefit from lower prices, while future generations would suffer from the loss of drug innovation.

Pharmaceutical companies also show a key role in the healthcare system because many patients trust their products. The values for drugs are increasing, and there are no covers to

Lastly, rivalry among existing competitors in the pharmaceutical industry is typically very high. There are large pharmaceutical acquisitions that have taken place over the last decade because everyone wants to improve their position in the marketplace. Through advertising, price competition and introducing new products, companies are able to compete for top spots in the industry to produce higher quality drugs at lower prices. However, for the EpiPen, product differentiation has provided them a competitive advantage, making competition low in the market place because there is nothing on the market that is

Whereas the Orphan Drug act promotes rare disease drug research and development, consequently, the negative effect of increasing patient drug costs can be attributed to the pharmaceutical industry’s practice of the exploitation of the act for profit and in their determination if orphan drugs are viable.

There are advantages of starting a pharmaceutical firm in India. It has emerged from being an enzyme-producing firm to a biotech powerhouse under the guidance of Ms Kiran M. Shaw. They have a well-established pharmaceutical industry that has been growing since 1947. After the purchase of Hindustan Antibiotics Ltd. and India Drug and Pharmaceuticals Ltd. they were able to compete with the MNC’s (Multi National Corporaton) from overseas (Kalegaonkar, Locke, Lehrich, 2008, p. 2). In the beginning the pharmaceutical industry saw substantial growth. “By the beginning of the 21st century, over 20,000 pharmaceutical companies were operating in India” (Kalegaonkar, Locke, Lehrich, 2008, p. 2). “The pharmaceutical industry in India is ranked third

PharmaCARE will not face any liability over its practices under current federal and state laws. Federal laws are vague and under reaching and in the case of CompCARE, the facility will not be classified as a drug manufacturer, which eliminates almost entirely the possibilities of regulation by current federal laws. The FDA does not consider compounded drugs to be as safe as those manufactured in large plants that have to meet standards for quality assurance and urges consumers to use FDA approved drugs. All though the FDA knows the risk of traditionally compounded drugs, the FDA doesn't know just how many compounding pharmacies exist in the United States. Also, states that do much of the regulation for compounding pharmacies are not themselves

As previously mentioned, application fees can reach up to $8000 and maintenance and examination fees can reach up to $650 per year. Since patents may need to be amended and the maintenance fees can accumulate leading to a costly application process. With high costs, after the approval of the patent, many companies charge higher prices for their products in order to recover their costs. This is especially prevalent in pharmaceutical companies who also charge high prices due to the costs of research and development. Pfizer patented a drug called Lipitor and after the expiry of the patent, the cost of Lipitor was “80% off the original cost” (Reference 11). When the drug is first introduced, the drug is the only product that that particular market for a certain medical condition. Therefore, with a monopoly, companies are able to charge higher prices to recuperate their costs from research and development as well as patent costs. However with the patents only protecting innovations for 20 years, patent cliffs occur where the patent expiration of drugs causes many other pharmaceutical companies to produce generic versions of the same drug. This can lead to revenue losses for the original pharmaceutical company as they had to invest significantly into their research and development while other

Medications are a critical player in the healthcare system, and are necessary to maintain or improve a certain level of health and wellness. As discussed in chapter one of our text, prescribed medications are considered a tertiary prevention in that they are to "reduce the impact of an already established disease by minimizing disease-related complications." (Niles, 2018, p.3) Medications are either brand name (meaning that the manufacturer has completed necessary research and development, marketing, as well as promoting) or generic. (Stoppler, n.d.) According to the FDA's web page on this topic (Center for Drug Evaluation and Research, n.d.), generic medications are developed when a manufacturer's exclusivity period is close to expiring,

After the generic is down for use, the pharmacy that used to buy a brand and pays four hundred dollars for just a hundred pills, now pays from one to ten dollars for a hundred pills which makes the expenses of the pharmacy decrease. (Belk David MD)

Once a company has successfully developed an orphan drug and gained FDA approval, the process to build and operate a manufacturing facility can be extremely costly. This is driven by the fact that the bargaining power of the supplies is medium/high. This classification is because of the extreme regulations that exist for not only the equipment, but also the raw materials used within the drug manufacturing process. The environment causes companies to create stringent supplier

Another important factor is the inefficient patent system that gives drug companies monopoly power, enabling them to charge such obscene prices for years. It is undisputed that pharmaceutical companies are the innovative engine for the discovery of new drugs. In 2012, according to Pharmaceutical Research and Manufacturers of America (“PhRMA”), pharmaceutical companies spent at least $48.5 billion on research and development. The new drug R&D process is costly, with average investment for each new drug approved standing at $1.2 billion due to the cost of failures.It was estimated that up to 10,000 compounds may be needed to produce one successful Food and Drug Administration (FDA)-approved drug. On the other hand, if we consider the profit then the

Yes, there is an impact on the pharmaceutical company, like those in the US as a result of differential prices between that country and other nations.

This report provides an analytical strategic review of the global pharmaceutical industry; its origin, evolution,